Patient outcomes are poor for aggressive B-cell non-Hodgkin's lymphomas not responding to or progressing within 12 months after first-line therapy. Tisagenlecleucel is an anti-CD19 chimeric antigen receptor T-cell therapy approved for diffuse large B-cell lymphoma after at least two treatment lines.

Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma

Santoro, Armando;
2022

Abstract

Patient outcomes are poor for aggressive B-cell non-Hodgkin's lymphomas not responding to or progressing within 12 months after first-line therapy. Tisagenlecleucel is an anti-CD19 chimeric antigen receptor T-cell therapy approved for diffuse large B-cell lymphoma after at least two treatment lines.
Adult
Aged
Antineoplastic Agents, Immunological
Antineoplastic Combined Chemotherapy Protocols
Combined Modality Therapy
Female
Humans
Lymphoma, Large B-Cell, Diffuse
Male
Middle Aged
Progression-Free Survival
Receptors, Antigen, T-Cell
Receptors, Chimeric Antigen
Salvage Therapy
Transplantation, Autologous
Hematopoietic Stem Cell Transplantation
Immunotherapy, Adoptive
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11699/66019
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 45
  • ???jsp.display-item.citation.isi??? ND
social impact